AXSM vs EXEL
Axsome Therapeutics, Inc. vs Exelixis — AI-powered side-by-side comparison
AXSM
Axsome Therapeutics, Inc.
55
Watch
VS
| Metric | AXSM | EXEL |
|---|
| AI Score |
55
|
67
|
| Price |
$215.92
|
$51.30
|
| P/E Ratio |
-57.54×
|
15.60×
|
| ROE |
-207.5%
|
36.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
93.2%
|
96.5%
|
| Debt / Equity |
2.63×
|
0.09×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
41.5
|
41.0
|
| Beta |
0.596
|
0.422
|
| Expected Upside |
—
|
+8.7%
|
AI Committee View
Current Innellis committee reasoning for AXSM versus EXEL.
EXEL leads by 12 points.
EXEL scores 67/100 (Buy) versus AXSM at 55/100 (Watch).
AXSM Committee View
50% agreement
4 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — bollinger bandwidth of 20.4% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Bollinger bandwidth of 20.4% signals elevated volatility — Risk
EXEL Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. The main limiting factor is price-to-book of 5.4x prices in significant intangible value. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 42.5% shows genuine earnings power backing the valuation — Value
- EPS growing 52.7% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- Price-to-book of 5.4x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical